Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PLK1 | P53350 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38791 | 0.87 | RAB9A (0.40) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL38704 | 0.87 | ALDH1A1 (0.44) | MAPTRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL38769 | 0.87 | ALDH1A1 (0.44) | MAPTRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL38682 | 0.86 | MAPT (0.43) | MAPTRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL38701 | 0.86 | MAPT (0.43) | MAPTRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL13959036 | 0.85 | MAPT (0.42) | MAPTRAB9ANPC1SMN1; SMN2ALDH1A1 | |
| SCHEMBL38663 | 0.82 | PPARA (0.51) | MAPTRAB9ANPC1L3MBTL1BCHE | |
| SCHEMBL43048 | 0.82 | PPARA (0.51) | MAPTRAB9ANPC1L3MBTL1BCHE | |
| SCHEMBL47175 | 0.79 | MAPT (0.62) | MAPTRAB9ANPC1SMN1; SMN2L3MBTL1 | |
| SCHEMBL12966546 | 0.79 | PPARA (0.57) | MAPTRAB9ANPC1L3MBTL1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8426390-B2 | Triazene compounds for the treatment of cancer | TRIN THERAPEUTICS GMBH (DE) | 2013-04-23 | — | — | US | disclosed |
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | TRIN THERAPEUTICS GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028927-A1 | Novel Triazene Compounds For The Treatment Of Cancer | KRAS, TP53, VHL | MAPT 1925/4885RAB9A 409/4885NPC1 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.